Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients … – GlobeNewswire

NEW YORK, Might 29, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical firm growing and delivering novel therapies for the administration of central nervous system (CNS) problems, in the present day introduced 5 displays, together with two featured oral plenary displays, on solriamfetol at SLEEP 2024, the thirty eighth annual assembly of the American Academy of Sleep Medication (AASM) and the Sleep Analysis Society (SRS), being held June 1-5, 2024, in Houston, Texas.

“Cognitive functioning is an underappreciated side of sleep problems. Typically overshadowed by clinically defining signs equivalent to EDS, impaired cognition includes important burden to affected person lives. The SHARP research of solriamfetol confirmed improved cognitive functioning in contributors with impaired cognition related to OSA and EDS,” stated Hans Van Dongen, PhD, Professor at Washington State College and presenting writer of the SHARP research plenary lecture. “As well as, solriamfetol demonstrated enhancements throughout measures of govt perform, reminiscence, and processing velocity.”

Particulars for the displays are as follows:

Title: Solriamfetol on Cognition in Obstructive Sleep Apnea with Extreme Daytime Sleepiness and Impaired Cognition
Lead Writer: Hans Van Dongen, PhD, Professor at Washington State College
Plenary Session: O-09
Plenary Date/Time: Tuesday, June 4 from 9:15-9:30 a.m. Central Time
Poster Session: P-45
Poster Quantity: 390
Poster Date/Time: Wednesday, June 5 from 11-11:45 a.m. Central Time

Title: Results of Solriamfetol on Cognition on Sufferers with Extreme Daytime Sleepiness Related to Narcolepsy
Lead Writer: Yaroslav Winter, MD, Mainz Complete Epilepsy and Sleep Medication Middle, Division of Neurology, Johannes Gutenberg-College, Mainz, Germany
Plenary Session: O-18
Plenary Date/Time: Tuesday, June 4 from 5-5:15 p.m. Central Time
Poster Session: P-13
Poster Quantity: 266
Poster Date/Time: Monday, June 3 from 11-11:45 a.m. Central Time

Title: Solriamfetol and Upkeep of Wakefulness Outcomes in Sufferers with Narcolepsy and Obstructive Sleep Apnea
Lead Writer: Dr. Michael Thorpy, Director of the Sleep-Wake Issues Middle on the Montefiore Medical Middle and Professor of Neurology at Albert Einstein Faculty of Medication
Poster Session: P-29
Poster Quantity: 324
Poster Date/Time: Tuesday, June 4 from 11-11:45 a.m. Central Time

Title: Actual-world Use of Solriamfetol for Extreme Daytime Sleepiness in Sufferers Reporting Anxiousness or Despair
Lead Writer: Ulf Kallweit is Assistant Professor of Neurology on the College Witten/Herdecke, Germany.
Poster Session: P-39
Poster Quantity: 200
Poster Date/Time: Wednesday, June 5 from 11-11:45 a.m. Central Time

Title: SURWEY: Remedy of Extreme Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes
Lead Writer: Samantha Floam, DMD, Axsome Therapeutics
Poster Session: P-29
Poster Quantity: 325
Poster Date/Time: Tuesday, June 4 from 10-10:45 a.m. Central Time

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical firm growing and delivering novel therapies for central nervous system (CNS) situations which have restricted therapy choices. By means of improvement of therapeutic choices with novel mechanisms of motion, we’re reworking the method to treating CNS situations. At Axsome, we’re dedicated to growing merchandise that meaningfully enhance the lives of sufferers and supply new therapeutic choices for physicians. For extra info, please go to the Firm’s web site at The Firm might often disseminate materials, nonpublic info on the corporate web site.

Ahead Trying Statements

Sure issues mentioned on this press launch are “forward-looking statements”. We might, in some instances, use phrases equivalent to “predicts,” “believes,” “potential,” “proceed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “might,” “might,” “would possibly,” “will,” “ought to” or different phrases that convey uncertainty of future occasions or outcomes to establish these forward-looking statements. Specifically, the Firm’s statements concerning tendencies and potential future outcomes are examples of such forward-looking statements. The forward-looking statements embody dangers and uncertainties, together with, however not restricted to, the continued business success of our Sunosi® and Auvelity® merchandise and the success of our efforts to acquire any further indication(s) with respect to solriamfetol and/or AXS-05; the success, timing and value of our ongoing scientific trials and anticipated scientific trials for our present product candidates, together with statements concerning the timing of initiation, tempo of enrollment and completion of the trials (together with our capacity to completely fund our disclosed scientific trials, which assumes no materials adjustments to our presently projected revenues or bills), futility analyses and receipt of interim outcomes, which aren’t essentially indicative of the ultimate outcomes of our ongoing scientific trials, and/or information readouts, and the quantity or sort of research or nature of outcomes essential to assist the submitting of a brand new drug software (“NDA”) for any of our present product candidates; our capacity to fund further scientific trials to proceed the development of our product candidates; the timing of and our capacity to acquire and preserve U.S. Meals and Drug Administration (“FDA”) or different regulatory authority approval of, or different motion with respect to, our product candidates, together with statements concerning the timing of any NDA submission; whether or not points recognized by FDA within the full response letter might impression the potential approvability of the Firm’s NDA for AXS-07 for the acute therapy of migraine in adults with or with out aura, pursuant to our particular protocol evaluation for the MOMENTUM scientific trial; the Firm’s capacity to efficiently defend its mental property or receive the mandatory licenses at a price acceptable to the Firm, if in any respect; the profitable implementation of the Firm’s analysis and improvement packages and collaborations; the success of the Firm’s license agreements; the acceptance by the market of the Firm’s merchandise and product candidates, if accepted; the Firm’s anticipated capital necessities, together with the quantity of capital required for the continued commercialization of Sunosi and Auvelity and for the Firm’s business launch of its different product candidates, if accepted, and the potential impression on the Firm’s anticipated money runway; unexpected circumstances or different disruptions to regular enterprise operations arising from or associated to geo-political conflicts or a world pandemic and different components, together with basic financial situations and regulatory developments, not inside the Firm’s management. The components mentioned herein might trigger precise outcomes and developments to be materially totally different from these expressed in or implied by such statements. The forward-looking statements are made solely as of the date of this press launch and the Firm undertakes no obligation to publicly replace such forward-looking statements to mirror subsequent occasions or circumstance.

Axsome Contacts:

Mark Jacobson
Chief Working Officer
Axsome Therapeutics, Inc.
One World Commerce Middle, 22nd Ground
New York, NY 10007
Tel: 212-332-3243
Electronic mail:

Darren Opland
Director, Company Communications
Axsome Therapeutics, Inc.
One World Commerce Middle, 22nd Ground
New York, NY 10007
Tel: 929-837-1065
Electronic mail:

Adblock check (Why?)

Leave a Reply

Your email address will not be published. Required fields are marked *